Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

NCT04308278 | Recruiting Phase 4

• 1 other identifier: LLB-2019-03
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 12

Brief Summary

Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response. Some individuals develop infectious mononucleosis (a self-limiting lymphoproliferative disorder in adolescents and young adults that is considered to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated lymphoid, or epithelial malignancies. Today, there is no available treatment to treat and destroy EBV. The treatment is essentially symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain for example. The studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is the same for the two drugs: it consists in taking the content of one capsule per day, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be of 6 months of continuous intake of the content of 1 capsule/day. The aim of this study is to provide additional information on effectiveness on the 2LEBV® and 2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV infection.

Conditions

EBV Infection

Outcome Measures

Primary Outcomes (1)

• Measure of the general fatigue scale of the Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire at the end of the treatment.

  Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome. General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.

  6 months

Secondary Outcomes (8)

• Comparison of the efficacy of the treatment on physical fatigue, reduced activity, reduced motivation and mental fatigue scales on the MFI-20 questionnaire between the 2LEBV® or the 2LXFS®/2LEBV® group versus the placebo group

  6 months

• Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.

  3 months

• Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.

  12 months

• Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.

  6 months

• Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.

  12 months

Study Arms (2)

2LEBV® / 2LXFS®

EXPERIMENTAL

6 months of treatment

Drug: 2LEBV® / 2LXFS®

Placebo

PLACEBO COMPARATOR

6 months of treatment

Drug: Placebo

Interventions

2LEBV® / 2LXFS® DRUG

The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

2LEBV® / 2LXFS®

Placebo DRUG

The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Placebo

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients, male or female, aged 12 years and older,
• Patient with fatigue for 1 month or more,
• Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders.
• Patient (and/or parents if necessary) agrees to perform serology for the study,
• Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study,
• Signature of the Informed Consent Form by the patient (and/or parents if necessary).
• \- Patient who have a positive serology for EBV (IgG and/or IgM positive).

You may not qualify if:

• Patient who have received any treatment with the 2LEBV® or 2LXFS®,
• Patients who have received any homeopathic treatment in the previous 2 months prior to the study,
• Patients under immunosuppressive treatment,
• Patient undergoing treatment for psychiatric disorders,
• Patients having received immunotherapy or micro-immunotherapy during the last 3 months,
• Patients with known lactose intolerance,
• Pregnant or breastfeeding women,
• Patients who participated in a clinical study in the previous 2-months period,
• Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study,
• Patients with severe immunodeficiency disease requiring long term treatment (\*) or patients under chemotherapy or radiotherapy,
• Patients under homeopathic or phytotherapy treatment,
• Patients addicted to or using recreational drugs,
• Patient under guardianship and/or curatorship, (\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.

Sponsors & Collaborators

• Labo'Life: lead

Study Sites (12)

Private Practice

Aartselaar, 2630, Belgium

RECRUITING

Private Practice

Boortmeerbeek, 3190, Belgium

TERMINATED

Private Practice

Brussels, 1040, Belgium

RECRUITING

Private practice

Brussels, 1040, Belgium

RECRUITING

Private Practice

Brussels, 1200, Belgium

RECRUITING

Private Practice

Ghent, 9000, Belgium

RECRUITING

Private Practice

Jette, 1090, Belgium

WITHDRAWN

Private Practice

Limal, 1300, Belgium

WITHDRAWN

Private practice

Marche-en-Famenne, 6900, Belgium

RECRUITING

Cabinet privé

Schoten, 2900, Belgium

RECRUITING

Private practice

Stavelot, 4790, Belgium

RECRUITING

Private practice

Waregem, 8790, Belgium

RECRUITING

MeSH Terms

Conditions

Epstein-Barr Virus Infections

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections

Central Study Contacts

Charlotte BOLLE

CONTACT

497 49 13 74; charlotte.bolle@labolife.com

Laura FERTE

CONTACT

499 71 79 64; laura.ferte@labolife.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2020
• First Posted: March 16, 2020
• Study Start: January 22, 2021
• Primary Completion (Estimated): August 22, 2026
• Study Completion (Estimated): August 30, 2026
• Last Updated: October 30, 2024

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

BE (12)